Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis

Published:2022-04-15 Issue:8 Volume:205 Page:936-948
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Khan Fasihul A.¹²^ORCID,Stewart Iain¹²³^ORCID,Moss Samuel¹²³,Fabbri Laura¹²³,Robinson Karen A.⁴,Johnson Simon R.¹²^ORCID,Jenkins R. Gisli¹²³

Affiliation:

1. Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham, United Kingdom;

2. Nottingham Biomedical Research Centre, National Institute for Health Research, Nottingham, United Kingdom;

3. National Heart and Lung Institute, Imperial College London, London, United Kingdom; and

4. Johns Hopkins University, Baltimore, Maryland

Funder

Nottingham National Institute for Health Research Biomedical Research Centre

National Institute for Health Research research professorship

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202109-2091OC

Reference23 articles.

1. The rising incidence of idiopathic pulmonary fibrosis in the UK

2. All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials

3. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

4. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

5. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of telomere dysfunction and immune infiltration in idiopathic pulmonary fibrosis: new insights from bioinformatics analysis;Frontiers in Genetics;2024-09-13

2. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2024-08-15

3. The future of clinical trials in idiopathic pulmonary fibrosis;Current Opinion in Pulmonary Medicine;2024-07-04

4. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments;JAMA;2024-05-21

5. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency;American Journal of Respiratory and Critical Care Medicine;2024-03-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3